TY - JOUR T1 - Forgotten Primodos story and the roles of general practitioners JF - BMJ Evidence-Based Medicine JO - BMJ EBM DO - 10.1136/bmjebm-2019-111307 SP - bmjebm-2019-111307 AU - Carl Heneghan AU - Jeffrey Aronson Y1 - 2020/01/23 UR - http://ebm.bmj.com/content/early/2020/01/22/bmjebm-2019-111307.abstract N2 - From 1958 to 1978, over a million women in the UK were subjected to hormone pregnancy tests (HPTs). The principal formulation marketed in the UK, by Schering Chemicals, was called Primodos. Prescribed mainly in general practice or given as free samples by the drug company, Primodos was marketed as a pregnancy test, more convenient than other available tests, such as the commonly used Hogben toad test, which was expensive and took 2 weeks to provide a result.1 Primodos contained oestrogen ethinylestradiol 20 μg and a large dose of the progestogen norethisterone, typically 10 mg, or 40 times the amount in today’s oral contraceptives. It worked by inducing menstrual-like bleeding in non-pregnant women; failure to bleed implied pregnancy.Because of suspicions of an association with congenital malformations, HPTs created considerable controversy.2 In 1967, the paediatrician Gal, working in a department of obstetrics and gynaecology, published evidence that they caused spina bifida.3 In 1970, the company withdrew pregnancy testing as an indication, but Primodos continued to be prescribed and handed out, because it was still available for treating secondary amenorrhoea. By 1975, a warning about the possible risk of congenital anomalies was added to the label, as was a contraindication in pregnancy. In June 1975, the Committee on Safety of Medicines (CSM) sent an alert to all UK doctors, advising that there might be an association between HPTs and congenital anomalies, and recommending that ‘this method should not now normally be used’. In 1977, the CSM wrote again, saying that the association had been confirmed (see figure 1). This time they wrote that HPTs ‘should not be used’. In 1978, Primodos was removed from the UK market because of concerns about teratogenicity and falling sales. At the time, the Association for Children Damaged by … ER -